The new opportunities of treatment of non-alcoholic steatohepatitis
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 1
Abstract
Objective — to evaluate the efficacy and safety of the dietary supplement Schisandrin®, 250 mg tablets (manufacturer Pharmacom Ltd.) in patients with non-alcoholic steatohepatitis. Materials and methods. The investigation involved 40 patients (18 (45 %) men and 22 (55 %) women) with non-alcoholic steatohepatitis (NASH), aged 25 to 65 years old (the mean age 43.6 ± 11.3 years). The control group consisted of 10 healthy subjects. Clinical examinations included assessment of data of anthropometric measuring, blood pressure, determination of serum levels of C-reactive protein (CRP) and TNF-alpha in serum, degree of liver steatosis. The treatment was performed with the drug Schisandrin® for 12 weeks in different dosage regimens: I group — 20 patients receiving the drug Schisandrin® 1 tablet 3 times a day; II group — 20 patients who received the drug Schisandrin® for 2 tablets 3 times a day. Results. In the course of treatment, there was a significant dynamics of the main clinical manifestations, i.e. symptoms’ removal or relief, which more rapidly and substantially reduced in patients of group II, as well as decreased activity of the inflammatory process in the liver tissue. The intake of Schisandrin® significantly reduced the increased ALT and AST activity and level of cholestasis markers in patients with NASH, this effect was dose-dependent, too. By the end of third months of therapy, a decrease in the level of high-sensitivity CRP and serum TNF-α levels in the examined patients was achieved, more substantial changes were observed in patients of group II. The improvement of ultrasound characteristics has been revealed, including tendency towards normalization of the acoustic density and liver size due reduction of steatosis degree. Conclusions. It has been demonstrated that Schisandrin® had a positive effects on the NASH course, with a higher efficacy and dose-dependent effects in the treatment regimen of 2 tablets 3 times a day for 3 months. This dose proved to be highly safe and well tolerated. Schisandrin® can serve as an alternative to the treatment of patients with non-alcoholic fatty liver disease at the NASH stage, not only in the stage of activation of the inflammatory process in the liver tissue, but also at the stage of supportive therapy in order to prevent the disease progression.
Authors and Affiliations
G. D. Fadieienko, O. V. Kolesnikova, T. A. Solomenseva
Keywords
Related Articles
- EP ID EP276249
- DOI -
- Views 125
- Downloads 0
Autoimmune gastritis: problems of diagnosis and therapy
Chronic gastritis (CG) is one of the most widespread internal diseases, which affects up to 20 % of the adult population. The modern CG paradigm considers disease as a launchpad for the formation of stomach cancer, as we...
Issues of concern in the diagnosis, treatment and eradication control for the Helicobacter pylori infection at the stage of primary healthcare (based on the results of questioning of primary care physicians)
Objective — based on the results of questioning of primary care physicians, to investigate the status of their awareness regarding the diagnosis, treatment and eradication control for the Helicobacter pylori infection in...
The diseases of the upper part of gastrointestinal tract: risk factors
The authors present results of clinical and statistic investigation devoted to the study on influence of various risk factors (age, sex, pernicious habits, dietetic regimen, occupational hazards etc.) on the development...
Efficiency and safety of ademetionine in the correction of liver function in patients with steatohepatitis. The results of an open comparative post-marketing study.
Objective — to study the efficacy and safety of ademetionine in patients with non-alcoholic steatohepatitis (NASH). Materials and methods. Examinations involved 60 patients with NASH, who were divided into two groups. Pa...
The role of thyroid hormones in the formation mechanisms of motor-secretory disorders in patients with gastroesophageal reflux disease with concomitant autoimmune thyroiditis
Objective — to study the role of thyroid hormones in the formation of motor-secretory disorders with the comorbid course of gastroesophageal reflux disease (GERD) and autoimmune thyroiditis (AIT). Materials and methods....